← Leaderboards
Russell E Ware
Duke University
$48,672,245
Attributed
$50,208,522
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.2M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$52,768,410 · 13
By mechanism
U01$24,762,189 · 2
R01$22,448,862 · 3
U54$4,935,555 · 6
K24$516,622 · 1
N01$105,182 · 1
Top collaborators
- James M Boyett3 shared
- Jane Silva Hankins3 shared
- Mary Elizabeth Mccarville3 shared
Most similar at Duke University
Same institution · by research overlap
- Marilyn J Telen$25,715,109
- William H Kane$4,042,669
- Michael Barry Kastan$65,974,699
- Katherine J. Franz$5,329,319
- Dorothy A Sipkins$8,543,606
Others in their field
Top investigators on “Sickle Cell Anemia”
- Michael Rutledge Debaun · Vanderbilt University Medical Center$38,268,866
- Martin H. Steinberg · Boston Medical Center$25,628,557
- Michael L. Terrin · Clinical Trials And Surveys Corporation$23,855,067
- Barbara L Kroner · Research Triangle Institute$21,141,016
- Garret A Fitzgerald · University Of Pennsylvania$20,602,198
- Robert J Adams · Medical College Of Georgia (Mcg)$18,246,639
Research focus
Sickle Cell AnemiaChildHydroxyureaLaboratoriesToxic EffectEventChronicMorbidity - Disease RateResearch PersonnelAffectFutureTrainingOrganDesignMedicalTransfusionCessation Of LifeLeadCollaborationsPharmacogenomicsDrug KineticsFundingSickle CellBlood
Grant awards (55)
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia$500,339
U01 · FY2025 · HL · contact PI
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia$282,506
U01 · FY2025 · HL · contact PI
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia$244,008
U01 · FY2025 · HL · contact PI
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia$196,803
U01 · FY2025 · HL · contact PI
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia$178,823
U01 · FY2025 · HL · contact PI
Enrichment$125,605
U54 · FY2025 · DK · contact PI
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia$19,975
U01 · FY2025 · HL · contact PI
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia$1,423,588
U01 · FY2024 · HL · contact PI
Enrichment$125,605
U54 · FY2024 · DK · contact PI
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia$1,431,382
U01 · FY2023 · HL · contact PI
Enrichment$125,605
U54 · FY2023 · DK · contact PI
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia$1,545,130
U01 · FY2022 · HL · contact PI
Enrichment$125,618
U54 · FY2022 · DK · contact PI
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia$675,820
U01 · FY2021 · HL · contact PI
Enrichment$125,605
U54 · FY2021 · DK · contact PI
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia$676,152
U01 · FY2020 · HL · contact PI
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia$676,152
U01 · FY2019 · HL · contact PI
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia$685,789
U01 · FY2018 · HL · contact PI
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia$769,765
U01 · FY2017 · HL · contact PI
Sparing Conversion to Abnormal TCD Elevation$401,529
R01 · FY2014 · HL · contact PI
TCD With Transfusions Changing to Hydroxyurea$3,207,307
R01 · FY2013 · HL · contact PI
TCD With Transfusions Changing to Hydroxyurea$4,029,847
R01 · FY2012 · HL · contact PI
Sparing Conversion to Abnormal TCD Elevation$598,911
R01 · FY2012 · HL · contact PI
TCD With Transfusions Changing to Hydroxyurea$3,664,789
R01 · FY2011 · HL · contact PI
Sparing Conversion to Abnormal TCD Elevation$653,799
R01 · FY2011 · HL · contact PI
Hydroxyurea Pharmacokinetics and Pharmacogenomics$398,080
R01 · FY2011 · HL · contact PI
Sickle Cell Scholar component$113,657
U54 · FY2011 · HL · contact PI
Administrative Core$69,839
U54 · FY2011 · HL · contact PI
TCD With Transfusions Changing to Hydroxyurea$4,177,447
R01 · FY2010 · HL · contact PI
Stroke with Transfusions Changing to Hydroxyurea$1,152,696
U01 · FY2010 · HL · contact PI
Sparing Conversion to Abnormal TCD Elevation$795,659
R01 · FY2010 · HL · contact PI
Hydroxyurea Pharmacokinetics and Pharmacogenomics$378,000
R01 · FY2010 · HL · contact PI
TCD With Transfusions Changing to Hydroxyurea$3,387,494
R01 · FY2009 · HL · contact PI
Stroke with Transfusions Changing to Hydroxyurea$2,545,955
U01 · FY2009 · HL · contact PI
Comprehensive Sickle Cell Center Composite:Basic & Translational Research Program$1,296,365
U54 · FY2009 · HL · contact PI
Hydroxyurea Pharmacokinetics and Pharmacogenomics$378,000
R01 · FY2009 · HL · contact PI
Sickle Cell Scholar component$304,279
U54 · FY2009 · HL · contact PI
Administrative Core$304,279
U54 · FY2009 · HL · contact PI
Stroke with Transfusions Changing to Hydroxyurea$3,101,582
U01 · FY2008 · HL · contact PI
Comprehensive Sickle Cell Center Composite$1,263,523
U54 · FY2008 · HL · contact PI
Hydroxyurea Pharmacokinetics and Pharmacogenomics$378,000
R01 · FY2008 · HL · contact PI
Sickle Cell Scholar component$176,137
U54 · FY2008 · HL · contact PI
Administrative Core$108,231
U54 · FY2008 · HL · contact PI
Stroke with Transfusions Changing to Hydroxyurea$2,804,348
U01 · FY2007 · HL · contact PI
CORE--Clinical Core$434,649
U54 · FY2007 · HL · contact PI
Stroke with Transfusions Changing to Hydroxyurea$3,207,047
U01 · FY2006 · HL · contact PI
CORE--Clinical Core$236,558
U54 · FY2006 · HL · contact PI
Stroke with Transfusions Changing to Hydroxyurea$2,644,329
U01 · FY2005 · HL
Genetic Modifiers in Children with Sickle Cell Anemia$107,405
K24 · FY2005 · HL
Genetic Modifiers in Children with Sickle Cell Anemia$105,638
K24 · FY2004 · HL
Genetic Modifiers in Children with Sickle Cell Anemia$103,396
K24 · FY2003 · HL
Genetic Modifiers in Children with Sickle Cell Anemia$101,172
K24 · FY2002 · HL
Genetic Modifiers in Children with Sickle Cell Anemia$99,011
K24 · FY2001 · HL
PEDIATRIC HYDROXYUREA PHASE III CLINICAL TRIAL$105,182
N01 · FY2000 · HB
PEDIATRIC HYDROXYUREA PHASE III CLINICAL TRIAL$0
N01 · FY2000 · HB